{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T01:54:57Z","timestamp":1785894897799,"version":"3.56.0"},"reference-count":33,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2018,8,1]],"date-time":"2018-08-01T00:00:00Z","timestamp":1533081600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,8,1]],"date-time":"2018-08-01T00:00:00Z","timestamp":1533081600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2018,8,1]],"date-time":"2018-08-01T00:00:00Z","timestamp":1533081600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2018,8,1]],"date-time":"2018-08-01T00:00:00Z","timestamp":1533081600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2018,8,1]],"date-time":"2018-08-01T00:00:00Z","timestamp":1533081600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2018,8,1]],"date-time":"2018-08-01T00:00:00Z","timestamp":1533081600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2018,8,1]],"date-time":"2018-08-01T00:00:00Z","timestamp":1533081600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100002347","name":"Bundesministerium f\u00fcr Bildung und Forschung","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002347","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008349","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008349","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005646","name":"Actelion Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005646","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015756","name":"Cilag","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015756","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000801","name":"Bayer HealthCare","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000801","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013327","name":"H. Lundbeck A\/S","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013327","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002347","name":"Bundesministerium f\u00fcr Bildung und Forschung","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002347","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006279","name":"St. Jude Medical","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006279","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["amjmed.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The American Journal of Medicine"],"published-print":{"date-parts":[[2018,8]]},"DOI":"10.1016\/j.amjmed.2018.03.024","type":"journal-article","created":{"date-parts":[[2018,4,11]],"date-time":"2018-04-11T12:24:00Z","timestamp":1523449440000},"page":"945-955.e3","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":31,"title":["Gender Differences in Antithrombotic Treatment for Newly Diagnosed Atrial Fibrillation: The GLORIA-AF Registry Program"],"prefix":"10.1016","volume":"131","author":[{"given":"Micha\u0142","family":"Mazurek","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Menno V.","family":"Huisman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth J.","family":"Rothman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miney","family":"Paquette","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Teutsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans-Christoph","family":"Diener","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergio J.","family":"Dubner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan L.","family":"Halperin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristina","family":"Zint","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lionel Riou","family":"Fran\u00e7a","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shihai","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory Y.H.","family":"Lip","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.amjmed.2018.03.024_bib0010","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1161\/01.CIR.98.10.946","article-title":"Impact of atrial fibrillation on the risk of death: the Framingham Heart Study","volume":"98","author":"Benjamin","year":"1998","journal-title":"Circulation"},{"key":"10.1016\/j.amjmed.2018.03.024_bib0015","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/S0002-9343(02)01236-6","article-title":"A population-based study of the long-term risks associated with atrial fibrillation: 20-year follow-up of the Renfrew\/Paisley study","volume":"113","author":"Stewart","year":"2002","journal-title":"Am J Med"},{"key":"10.1016\/j.amjmed.2018.03.024_bib0020","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1161\/01.STR.30.6.1223","article-title":"Factors associated with ischemic stroke during aspirin therapy in atrial fibrillation: analysis of 2012 participants in the SPAF I III Clinical Trials","volume":"30","author":"Hart","year":"1999","journal-title":"Stroke"},{"key":"10.1016\/j.amjmed.2018.03.024_bib0025","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1161\/CIRCULATIONAHA.105.553438","article-title":"Gender differences in the risk of ischemic stroke and peripheral embolism in atrial fibrillation: the anticoagulation and Risk factors in Atrial fibrillation (ATRIA) study","volume":"112","author":"Fang","year":"2005","journal-title":"Circulation"},{"key":"10.1016\/j.amjmed.2018.03.024_bib0030","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1111\/j.1538-7836.2012.04853.x","article-title":"Female sex as a risk factor for stroke in atrial fibrillation: a nationwide cohort study","volume":"10","author":"Mikkelsen","year":"2012","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.amjmed.2018.03.024_bib0035","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/j.amjcard.2015.12.040","article-title":"Gender differences of thromboembolic events in atrial fibrillation","volume":"117","author":"Cheng","year":"2016","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.amjmed.2018.03.024_bib0040","first-page":"385","article-title":"Female sex as an independent risk factor for stroke in atrial fibrillation: possible mechanisms","volume":"111","author":"Cove","year":"2014","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.amjmed.2018.03.024_bib0045","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1378\/chest.09-1584","article-title":"Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the Euro Heart Survey on Atrial Fibrillation","volume":"137","author":"Lip","year":"2010","journal-title":"Chest"},{"key":"10.1016\/j.amjmed.2018.03.024_bib0050","doi-asserted-by":"crossref","first-page":"2369","DOI":"10.1093\/eurheartj\/ehq278","article-title":"Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC)","volume":"31","author":"Camm","year":"2010","journal-title":"Eur Heart J"},{"key":"10.1016\/j.amjmed.2018.03.024_bib0055","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1093\/europace\/eus305","article-title":"2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation\u2013developed with the special contribution of the European Heart Rhythm Association","volume":"14","author":"Camm","year":"2012","journal-title":"Europace"},{"key":"10.1016\/j.amjmed.2018.03.024_bib0060","doi-asserted-by":"crossref","first-page":"2893","DOI":"10.1093\/eurheartj\/ehw210","article-title":"2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS","volume":"37","author":"Kirchhof","year":"2016","journal-title":"Eur Heart J"},{"key":"10.1016\/j.amjmed.2018.03.024_bib0070","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.joa.2013.03.002","article-title":"The APHRS's 2013 statement on antithrombotic therapy of patients with nonvalvular atrial fibrillation","volume":"29","author":"Ogawa","year":"2013","journal-title":"J Arrhythmia"},{"key":"10.1016\/j.amjmed.2018.03.024_bib0075","doi-asserted-by":"crossref","first-page":"2365","DOI":"10.1161\/01.CIR.103.19.2365","article-title":"New-onset atrial fibrillation: sex differences in presentation, treatment, and outcome","volume":"103","author":"Humphries","year":"2001","journal-title":"Circulation"},{"key":"10.1016\/j.amjmed.2018.03.024_bib0080","doi-asserted-by":"crossref","first-page":"1952","DOI":"10.1001\/jama.2012.3490","article-title":"Sex differences in stroke risk among older patients with recently diagnosed atrial fibrillation","volume":"307","author":"Avgil Tsadok","year":"2012","journal-title":"JAMA"},{"key":"10.1016\/j.amjmed.2018.03.024_bib0085","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/j.jacc.2006.10.047","article-title":"Gender-related differences in presentation, treatment, and outcome of patients with atrial fibrillation in Europe: a report from the Euro Heart Survey on Atrial Fibrillation","volume":"49","author":"Dagres","year":"2007","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.amjmed.2018.03.024_bib0090","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1093\/europace\/euu155","article-title":"Sex-related differences in presentation, treatment, and outcome of patients with atrial fibrillation in Europe: a report from the Euro Observational Research Programme Pilot survey on Atrial Fibrillation","volume":"17","author":"Lip","year":"2015","journal-title":"Europace"},{"key":"10.1016\/j.amjmed.2018.03.024_bib0095","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.ahj.2013.12.006","article-title":"Design and rationale of Global Registry on Long-Term Oral Antithrombotic Treatment in Patients with Atrial Fibrillation: a global registry program on long-term oral antithrombotic treatment in patients with atrial fibrillation","volume":"167","author":"Huisman","year":"2014","journal-title":"Am Heart J"},{"key":"10.1016\/j.amjmed.2018.03.024_bib0100","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1378\/chest.10-0134","article-title":"A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: The Euro Heart survey","volume":"138","author":"Pisters","year":"2010","journal-title":"Chest"},{"key":"10.1016\/j.amjmed.2018.03.024_bib0105","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1093\/oxfordjournals.aje.a114212","article-title":"Binomial regression in GLIM: estimating risk ratios and risk differences","volume":"123","author":"Wacholder","year":"1986","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.amjmed.2018.03.024_bib0110","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1160\/TH11-05-0364","article-title":"Risks of thromboembolism and bleeding with thromboprophylaxis in patients with atrial fibrillation: a net clinical benefit analysis using a \u201creal world\u201d nationwide cohort study","volume":"106","author":"Olesen","year":"2011","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.amjmed.2018.03.024_bib0115","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.pcad.2015.07.003","article-title":"Oral anticoagulant therapy in atrial fibrillation patients at high stroke and bleeding risk","volume":"58","author":"Potpara","year":"2015","journal-title":"Prog Cardiovasc Dis"},{"key":"10.1016\/j.amjmed.2018.03.024_bib0120","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1093\/europace\/euv068","article-title":"Non-vitamin K antagonist oral anticoagulants and atrial fibrillation guidelines in practice: barriers to and strategies for optimal implementation","volume":"17","author":"Camm","year":"2015","journal-title":"Europace"},{"key":"10.1016\/j.amjmed.2018.03.024_bib0125","doi-asserted-by":"crossref","first-page":"27410","DOI":"10.1038\/srep27410","article-title":"Stroke and thromboembolic event rates in atrial fibrillation according to different guideline treatment thresholds: a nationwide cohort study","volume":"6","author":"Nielsen","year":"2016","journal-title":"Sci Rep"},{"key":"10.1016\/j.amjmed.2018.03.024_bib0130","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.117.005801","article-title":"Sex Differences in the Use of Oral Anticoagulants for Atrial Fibrillation: a report from the National Cardiovascular Data Registry (NCDR \u00ae) PINNACLE Registry","volume":"6","author":"Thompson","year":"2017","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.amjmed.2018.03.024_bib0135","first-page":"e199","article-title":"2014 AHA\/ACC\/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society","volume":"130","author":"January","year":"2014","journal-title":"Circulation"},{"key":"10.1016\/j.amjmed.2018.03.024_bib0140","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1016\/j.jacc.2015.01.044","article-title":"Oral anticoagulation, aspirin, or no therapy in patients with nonvalvular AF with 0 or 1 stroke risk factor based on the CHA2DS2-VASc score","volume":"65","author":"Lip","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.amjmed.2018.03.024_bib0145","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1378\/chest.15-1622","article-title":"Oral anticoagulation and the risk of stroke or death in patients with atrial fibrillation and one additional stroke risk factor: the Loire Valley atrial fibrillation project","volume":"149","author":"Fauchier","year":"2016","journal-title":"Chest"},{"key":"10.1016\/j.amjmed.2018.03.024_bib0150","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/j.jacc.2014.11.046","article-title":"Should atrial fibrillation patients with 1 additional risk factor of the CHA2DS2-VASc Score (Beyond Sex) receive oral anticoagulation?","volume":"65","author":"Chao","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.amjmed.2018.03.024_bib0155","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.jacc.2014.10.052","article-title":"Benefit of anticoagulation unlikely in patients with atrial fibrillation and a CHA2DS2-VASc score of 1","volume":"65","author":"Friberg","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.amjmed.2018.03.024_bib0160","first-page":"1114","article-title":"2014 focused update of the Canadian Cardiovascular Society guidelines for the management of atrial fibrillation","volume":"30","author":"Verma","year":"2014","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.amjmed.2018.03.024_bib0165","first-page":"24","article-title":"Atrial fibrillation patients categorized as \u201cNot for Anticoagulation\u201d according to the 2014 Canadian Cardiovascular Society algorithm are not \u201cLow Risk","volume":"31","author":"Lip","year":"2015","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.amjmed.2018.03.024_bib0170","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1161\/CIRCULATIONAHA.117.029081","article-title":"Female sex is a risk modifier rather than a risk factor for stroke in atrial fibrillation","volume":"8","author":"Nielsen","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.amjmed.2018.03.024_bib0175","first-page":"2376","article-title":"Regional differences in antithrombotic treatment for atrial fibrillation: insights from the GLORIA-AF Phase II Registry","volume":"12","author":"Mazurek","year":"2017","journal-title":"Thromb Haemost"}],"container-title":["The American Journal of Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000293431830305X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000293431830305X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T10:28:45Z","timestamp":1762079325000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S000293431830305X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8]]},"references-count":33,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2018,8]]}},"alternative-id":["S000293431830305X"],"URL":"https:\/\/doi.org\/10.1016\/j.amjmed.2018.03.024","relation":{},"ISSN":["0002-9343"],"issn-type":[{"value":"0002-9343","type":"print"}],"subject":[],"published":{"date-parts":[[2018,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Gender Differences in Antithrombotic Treatment for Newly Diagnosed Atrial Fibrillation: The GLORIA-AF Registry Program","name":"articletitle","label":"Article Title"},{"value":"The American Journal of Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.amjmed.2018.03.024","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}